Reimbursement uncertainty as healthcare payers globally shift toward value-based care models requiring robust health economics data demonstrating cost savings versus established CAD diagnostic pathways, which Acarix has not yet comprehensively proven at scale
Technological obsolescence risk from competing non-invasive CAD detection modalities including AI-enhanced ECG analysis, advanced biomarker panels, and coronary CT with fractional flow reserve that may offer superior diagnostic accuracy or workflow integration
Regulatory pathway complexity for novel diagnostic modalities lacking established predicate devices, particularly FDA clearance uncertainty that could delay or prevent US market entry representing 40%+ of global medtech opportunity
Entrenched competition from established cardiac diagnostic players (GE Healthcare, Siemens Healthineers, Philips) with existing hospital relationships, service networks, and bundled equipment contracts that create high switching costs
Clinical adoption inertia as cardiologists remain anchored to stress testing and CT angiography protocols embedded in practice guidelines, requiring extensive clinical evidence generation and key opinion leader advocacy to shift referral patterns
Equity dilution risk from ongoing capital requirements to fund cash burn estimated at $3-5M+ annually based on -121.2% FCF yield, with 9.47x current ratio suggesting 12-18 month runway before next financing event
Going concern risk if unable to secure additional financing or achieve commercial inflection, particularly acute given microcap status ($0.0B market cap) limiting access to institutional capital and creating illiquidity for existing investors
StructuralCompetitiveBalance Sheet
